Back
ESC Premium Access

CYP2C19 genotyping as complementary tool for guidance of early de-escalation of antiplatelet treatment in acute coronary syndrome patients

Session: Poster Session 6 - Pharmacogenetics - New sights on the horizon
Topic: Pharmacogenetics
Speaker: Doctor L. Gross (Munich, DE)
Event: ESC Congress 2018

Congress Presentation

Add to my library

Like

About the speaker

Doctor Lisa Gross

Ludwig Maximilians University, Munich (Germany)
0 follower

5 more presentations in this session

HDL-cholesterol dysfunction and inflammation in patients with genotypes associated with different responses to dalcetrapib

Speaker: Doctor A. Franci (Sao Paulo, BR)

Access
Abstract
Slides
Like
Thumbnail

Association of CYP2C19*2 and PEAR1 gene variant with platelet reactivity and clinical outcomes in patients undergoing stenting and treated with aspirin and clopidogrel

Speaker: Doctor K. Xu (Shanghai, CN)

Access
Abstract
Slides
Like
Thumbnail

Prasugrel or clopidogrel in non-st-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention

Speaker: Doctor S. Kim (Busan, KR)

Access
Abstract
Slides
Like
Thumbnail

Comparison of three different platelet function tests in patients on P2Y12 inhibitors in correlation to genetic background.

Speaker: Mrs R. Olie (Maastricht, NL)

Access
Abstract
Like
Thumbnail

Genetic influence on warfarin dose determination

Speaker: Doctor J. Li (Busan, KR)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Poster Session 6 - Pharmacogenetics - New sights on the horizon

Speakers: Doctor L. Gross, Doctor A. Franci, Doctor K. Xu, Doctor S. Kim, Mrs R. Olie...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources